
Ophthalmic Drugs Contract Manufacturing Market Report 2023-2033
Description
Ophthalmic Drugs Contract Manufacturing Market Report 2023-2033
The Ophthalmic Drugs Contract Manufacturing Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Factors Such As increasing prevalence of ophthalmic disorders and cost efficiency provided by CDMOs are driving the market growth
Several important elements that support the expansion and significance of the ophthalmic drugs contract manufacturing market in the pharmaceutical industry. One of the main causes is the rising incidence of ocular conditions like age-related macular degeneration (AMD), glaucoma, cataracts, and dry eye syndrome. Pharmaceutical companies are looking for effective drug manufacturing solutions as the aging population increases and lifestyle habit changes and there is an increasing need for effective pharmaceuticals to treat and maintain these eye problems.
Additionally, by outsourcing manufacturing to the CDMOs, enables pharmaceutical businesses to concentrate on their core capabilities, such as research and marketing. This strategic partnership shortens the time of ophthalmic medications to reach the market and thereby streamlining drug development process. Modern technologies and strong quality control procedures used by CDMOs guarantee the creation of high-quality medicines that satisfy market needs and regulatory requirements.
Economical effectiveness one of the major factor driving these companies to adopt CDMO services as it takes a significant financial investment in staff, facilities, and equipment to develop new pharmaceutical goods. Companies want to reduce the overall the cost and labour costs through outsourcing to the CDMOs.
Since CDMOs already have the necessary resources and knowledge, producing drugs, it turns to be a less expensive and involves fewer risks for investors.
Complex regulatory framework may pose as challenges in the ophthalmic drugs contract manufacturing market
Noncompliance with regulatory standards and poor pharmaceutical quality can have severe consequences for a business and its brand reputation. Therefore, adherence to regulatory rules is crucial in the pharmaceutical industry. Contract development and manufacturing organizations (CDMOs) face challenges in ensuring compliance with varying regulatory requirements across different regions and countries, particularly in the ophthalmic drug contract manufacturing industry.
As pharmaceutical companies outsource drug manufacturing to specialized CDMOs focusing on ophthalmic products, they encounter a complex web of diverse regulatory frameworks. Each region has its distinct guidelines, standards, and procedures governing various aspects of ophthalmic drug manufacturing and distribution. This includes quality control, safety assessments, and labelling, packaging, and distribution practices. Complying with these unique requirements demands a meticulous approach from contract manufacturers to ensure full compliance with the specific regulations of the markets they serve. This aspect could potentially limit the expansion of the pharmaceutical CDMO market in the coming years.
What Questions Should You Ask before Buying a Market Research Report?
Forecasts to 2033 and other analyses reveal commercial prospects
Segments Covered in the Report
Product Type
North America
Leading companies and the potential for market growth
How will the Ophthalmic Drugs Contract Manufacturing market, 2023 to 2033 report help you?
In summary, our 330+ page report provides you with the following knowledge:
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Ophthalmic Drugs Contract Manufacturing market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..
The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.
Table of Contents
334 Pages
- 1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Ophthalmic Drugs Contract Manufacturing Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2 Executive Summary
- 3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 High cost of in-house drug development is likely to propel the market growth
- 3.2.1.2 Growing prevalence of ophthalmic disorders
- 3.2.1.3 Reduced overall cost and time to the market
- 3.2.1.4 Ease of Supply Chain Issues and Bandwidth to Focus on Core Competencies
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Varying regulatory requirements across regions
- 3.2.2.2 Introduction of Serialization
- 3.2.3 Market Opportunities
- 3.2.3.1 Growth in Emerging Markets
- 3.2.3.2 Scalability and flexible production capacity
- 3.2.3.3 Specialized Services for Niche Markets and Late-Stage Customization
- 3.2.3.4 Process Improvement with better AI, e-Platforms, real time and remote tracing
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter’s Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers (Medium)
- 3.4.2 Bargaining Power of Buyers (Medium to High)
- 3.4.3 Competitive Rivalry (High)
- 3.4.4 Threat from Substitutes (Medium)
- 3.4.5 Threat of New Entrants (High)
- 3.5 PEST Analysis
- 3.5.1 Political
- 3.5.2 Economical
- 3.5.3 Social
- 3.5.4 Technological
- 4 Ophthalmic Drugs Contract Manufacturing Market Analysis by Product Type
- 4.1 Key Findings
- 4.2 Product Type Segment: Market Attractiveness Index
- 4.3 Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 4.4 APIs
- 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
- 4.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.5 FDFs
- 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
- 4.5.2 Market Share by Region, 2023 & 2033 (%)
- 4.5.3 FDFs in Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 5 Ophthalmic Drugs Contract Manufacturing Market Analysis by Primary Packaging
- 5.1 Key Findings
- 5.2 Primary Packaging Segment: Market Attractiveness Index
- 5.3 Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 5.4 Ampoules & Vials
- 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
- 5.4.2 Market Share by Region, 2023 & 2033 (%)
- 5.5 Glass & Plastic Bottles
- 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
- 5.6 Ointment Tubes
- 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
- 5.6.2 Market Share by Region, 2023 & 2033 (%)
- 5.7 Others
- 5.7.1 Market Size by Region, 2023-2033 (US$ Million)
- 5.7.2 Market Share by Region, 2023 & 2033 (%)
- 6 Ophthalmic Drugs Contract Manufacturing Market Analysis by Scale of Manufacturing
- 6.1 Key Findings
- 6.2 Scale of Manufacturing Segment: Market Attractiveness Index
- 6.3 Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 6.4 Preclinical
- 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
- 6.4.2 Market Share by Region, 2023 & 2033 (%)
- 6.5 Clinical
- 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
- 6.5.2 Market Share by Region, 2023 & 2033 (%)
- 6.6 Commercial
- 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
- 6.6.2 Market Share by Region, 2023 & 2033 (%)
- 7 Ophthalmic Drugs Contract Manufacturing Market Analysis by Company Size
- 7.1 Key Findings
- 7.2 Company Size Segment: Market Attractiveness Index
- 7.3 Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 7.4 Small Size
- 7.4.1 Market Size by Region, 2023-2033 (US$ Million)
- 7.4.2 Market Share by Region, 2023 & 2033 (%)
- 7.5 Mid-Sized
- 7.5.1 Market Size by Region, 2023-2033 (US$ Million)
- 7.5.2 Market Share by Region, 2023 & 2033 (%)
- 7.6 Large Sized
- 7.6.1 Market Size by Region, 2023-2033 (US$ Million)
- 7.6.2 Market Share by Region, 2023 & 2033 (%)
- 8 Ophthalmic Drugs Contract Manufacturing Market Analysis by Indication
- 8.1 Key Findings
- 8.2 Indication Segment: Market Attractiveness Index
- 8.3 Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 8.4 Age-Related Macular Degeneration
- 8.4.1 Market Size by Region, 2023-2033 (US$ Million)
- 8.4.2 Market Share by Region, 2023 & 2033 (%)
- 8.5 Glaucoma
- 8.5.1 Market Size by Region, 2023-2033 (US$ Million)
- 8.5.2 Market Share by Region, 2023 & 2033 (%)
- 8.6 Uveitis
- 8.6.1 Market Size by Region, 2023-2033 (US$ Million)
- 8.6.2 Market Share by Region, 2023 & 2033 (%)
- 8.7 Dry Eye Disease
- 8.7.1 Market Size by Region, 2023-2033 (US$ Million)
- 8.7.2 Market Share by Region, 2023 & 2033 (%)
- 8.8 Others
- 8.8.1 Market Size by Region, 2023-2033 (US$ Million)
- 8.8.2 Market Share by Region, 2023 & 2033 (%)
- 9 Ophthalmic Dug Contract Manufacturing Market Analysis by Region
- 9.1 Key Findings
- 9.2 Regional Market Size Estimation and Forecast
- 10 North America Ophthalmic Drugs Contract Manufacturing Market Analysis
- 10.1 Key Findings
- 10.2 North America Ophthalmic Drug Contract Manufacturing Market Attractiveness Index
- 10.3 North America Ophthalmic Drugs Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
- 10.4 North America Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Country
- 10.5 North America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 10.5.1 North America FDFs Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 10.6 North America Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 10.7 North America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 10.8 North America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 10.9 North America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 10.10 U.S. Ophthalmic Drugs Contract Manufacturing Market Analysis
- 10.11 Canada Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11 Europe Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.1 Key Findings
- 11.2 Europe Ophthalmic Drugs Contract Manufacturing Market Attractiveness Index
- 11.3 Europe Ophthalmic Drugs Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
- 11.4 Europe Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Country
- 11.5 Europe Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 11.5.1 Europe FDFs in Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 11.6 Europe Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 11.7 Europe Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 11.8 Europe Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 11.9 Europe Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 11.10 Germany Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.11 UK Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.12 France Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.13 Italy Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.14 Spain Ophthalmic Drugs Contract Manufacturing Market Analysis
- 11.15 Rest of Europe Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.1 Key Findings
- 12.2 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Attractiveness Index
- 12.3 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
- 12.4 Asia Pacific Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Country
- 12.5 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 12.5.1 Asia Pacific FDFs in Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 12.6 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 12.7 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 12.8 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 12.9 Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 12.10 Japan Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.11 China Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.12 India Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.13 Australia Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.14 South Korea Ophthalmic Drugs Contract Manufacturing Market Analysis
- 12.15 Rest of Asia Pacific Ophthalmic Drugs Contract Manufacturing Market Analysis
- 13 Latin America Ophthalmic Drugs Contract Manufacturing Market Analysis
- 13.1 Key Findings
- 13.2 Latin America Ophthalmic Drugs Contract Manufacturing Market Attractiveness Index
- 13.3 Latin America Ophthalmic Drugs Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
- 13.4 Latin America Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Country
- 13.5 Latin America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 13.5.1 Latin America FDFs in Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 13.6 Latin America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 13.7 Latin America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 13.8 Latin America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 13.9 Latin America Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 13.10 Brazil Ophthalmic Drugs Contract Manufacturing Market Analysis
- 13.11 Mexico Ophthalmic Drugs Contract Manufacturing Market Analysis
- 13.12 Rest of Latin America Ophthalmic Drugs Contract Manufacturing Market Analysis
- 14 MEA Ophthalmic Drugs Contract Manufacturing Market Analysis
- 14.1 Key Findings
- 14.2 MEA Ophthalmic Drugs Contract Manufacturing Market Attractiveness Index
- 14.3 MEA Ophthalmic Drugs Contract Manufacturing Market by Country, 2023, 2028 & 2033 (US$ Million)
- 14.4 MEA Ophthalmic Drug Contract Manufacturing Market Size Estimation and Forecast by Country
- 14.5 MEA Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 14.5.1 MEA FDFs in Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Product Type
- 14.6 MEA Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Primary Packaging
- 14.7 MEA Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Scale of Manufacturing
- 14.8 MEA Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Company Size
- 14.9 MEA Ophthalmic Drugs Contract Manufacturing Market Size Estimation and Forecast by Indication
- 14.10 GCC Ophthalmic Drugs Contract Manufacturing Market Analysis
- 14.11 South Africa Ophthalmic Drugs Contract Manufacturing Market Analysis
- 14.12 Rest of MEA Ophthalmic drug contract manufacturing Market Analysis
- 15 Company Profiles
- 15.1 Competitive Landscape, 2022
- 15.2 Strategic Outlook
- 15.3 Lonza
- 15.3.1 Company Snapshot
- 15.3.2 Company Overview
- 15.3.3 Financial Analysis
- 15.3.3.1 Net Revenue, 2018-2022
- 15.3.3.2 R&D, 2018-2022
- 15.3.4 Services Offered
- 15.3.5 Strategic Outlook
- 15.4 Recipharm
- 15.4.1 Company Snapshot
- 15.4.2 Company Overview
- 15.4.3 Financial Analysis
- 15.4.3.1 Net Revenue, 2018-2022
- 15.4.4 Services Offered
- 15.4.5 Strategic Outlook
- 15.5 Catalent Inc.
- 15.5.1 Company Snapshot
- 15.5.2 Company Overview
- 15.5.3 Financial Analysis
- 15.5.3.1 Net Revenue, 2018-2022
- 15.5.3.2 R&D, 2018-2022
- 15.5.3.3 Regional Market Shares, 2022
- 15.5.4 Services Offered
- 15.5.5 Strategic Outlook
- 15.6 Eurofins Scientific
- 15.6.1 Company Snapshot
- 15.6.2 Company Overview
- 15.6.3 Financial Analysis
- 15.6.3.1 Net Revenue, 2018-2022
- 15.6.3.2 Regional Market Shares, 2022
- 15.6.4 Services Offered
- 15.6.5 Strategic Outlook
- 15.7 Thermo Fisher Scientific Inc.
- 15.7.1 Company Snapshot
- 15.7.2 Company Overview
- 15.7.3 Financial Analysis
- 15.7.3.1 Net Revenue, 2018-2022
- 15.7.3.2 Regional Market Shares, 2022
- 15.7.4 Services Offered
- 15.7.5 Strategic Outlook
- 15.8 Unither Pharmaceuticals
- 15.8.1 Company Snapshot
- 15.8.2 Company Overview
- 15.8.3 Services Offering
- 15.8.4 Strategic Outlook
- 15.9 Laboratorios Salvat, S.A.
- 15.9.1 Company Snapshot
- 15.9.2 Company Overview
- 15.9.3 Services Offered
- 15.9.4 Strategic Outlook
- 15.10 Siegfried Holding AG
- 15.10.1 Company Snapshot
- 15.10.2 Company Overview
- 15.10.3 Financial Analysis
- 15.10.3.1 Net Revenue, 2018-2022
- 15.10.3.2 R&D, 2018-2022
- 15.10.4 Services Offered
- 15.10.5 Strategic Outlook
- 15.11 Pillar5 Pharma
- 15.11.1 Company Snapshot
- 15.11.2 Company Overview
- 15.11.3 Service Offering
- 15.11.4 Strategic Outlook
- 15.12 Abbvie Inc.
- 15.12.1 Company Snapshot
- 15.12.2 Company Overview
- 15.12.3 Service Offerings
- 15.12.4 Strategic Outlook
- 15.13 Jubilant HollisterStier LLC
- 15.13.1 Company Snapshot
- 15.13.2 Company Overview
- 15.13.3 Service Offerings
- 15.13.4 Strategic Outlook
- 15.14 Glenmark Pharmaceuticals
- 15.14.1 Company Snapshot
- 15.14.2 Company Overview
- 15.14.3 Financial Analysis
- 15.14.3.1 Net Revenue, 2018-2022
- 15.14.3.2 R&D, 2021-2022
- 15.14.4 Product Benchmarking
- 15.15 Merck KGaA
- 15.15.1 Company Snapshot
- 15.15.2 Company Overview
- 15.15.3 Financial Analysis
- 15.15.3.1 Net Revenue, 2018-2022
- 15.15.3.2 R&D, 2018-2022
- 15.15.3.3 Regional Market Shares, 2022
- 15.15.4 Service Offerings
- 15.15.5 Strategic Outlook
- 16 Conclusion and Recommendations
- 16.1 Concluding Remarks from Visiongain
- 16.2 Recommendations for Market Players
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.